Aspirin for Primary and Secondary Prevention of Mortality, Cardiovascular Disease, and Kidney Failure in the Chronic Renal Insufficiency Cohort (CRIC) Study
Jonathan J. Taliercio,Georges Nakhoul,Ali Mehdi,Wei Yang,Daohang Sha,Jesse D. Schold,Scott Kasner,Matthew Weir,Mohamed Hassanein,Sankar D. Navaneethan,Geetha Krishnan,Radhika Kanthety,Alan S. Go,Rajat Deo,Claudia M. Lora,Bernard G. Jaar,Teresa K. Chen,Jing Chen,Jiang He,Mahboob Rahman,CRIC study Investigators,Lawrence J. Appel,Debbie L. Cohen,Harold I. Feldman,James P. Lash,Robert G. Nelson,Panduranga S. Rao,Vallabh O. Shah,Mark L. Unruh
DOI: https://doi.org/10.1016/j.xkme.2022.100547
2022-11-01
Kidney Medicine
Abstract:Rationale and Objective: <AbstractText Label="Rationale and Objective" NlmCategory="UNASSIGNED">Chronic kidney disease is a risk enhancing factor for cardiovascular disease (CVD) and mortality, and the role of aspirin use is unclear in this population. We investigated the risk and benefits of aspirin use in primary and secondary prevention of CVD in the Chronic Renal Insufficiency Cohort Study.</AbstractText>Study Design: <AbstractText Label="Study Design" NlmCategory="UNASSIGNED">Prospective observational cohort.</AbstractText>Setting & Participants: <AbstractText Label="Setting & Participants" NlmCategory="UNASSIGNED">3,664 Chronic Renal Insufficiency Cohort participants.</AbstractText>Exposure: <AbstractText Label="Exposure" NlmCategory="UNASSIGNED">Aspirin use in patients with and without preexisting CVD.</AbstractText>Outcomes: <AbstractText Label="Outcomes" NlmCategory="UNASSIGNED">Mortality, composite and individual CVD events (myocardial infarction, stroke, and peripheral arterial disease), kidney failure (dialysis and transplant), and major bleeding.</AbstractText>Analytical Approach: <AbstractText Label="Analytical Approach" NlmCategory="UNASSIGNED">Intention-to-treat analysis and multivariable Cox proportional hazards model to examine associations of time varying aspirin use.</AbstractText>Results: <AbstractText Label="Results" NlmCategory="UNASSIGNED">The primary prevention group was composed of 2,578 (70.3%) individuals. Mean age was 57 ± 11 years, 46% women, 42% Black, and 47% had diabetes. The mean estimated glomerular filtration rate was 45 mL/min/1.73 m<sup>2</sup>. Median follow-up was 11.5 (IQR, 7.4-13) years. Aspirin was not associated with all-cause mortality in those without preexisting cardiovascular disease (CVD) (HR, 0.84; 95% CI, 0.7-1.01; <i>P</i> = 0.06) or those with CVD (HR, 0.88; 95% CI, 0.77-1.02, <i>P</i> = 0.08). Aspirin was not associated with a reduction of the CVD composite in primary prevention (HR, 0.97; 95% CI, 0.77-1.23; <i>P</i> = 0.79) and in secondary prevention because the original study design was not meant to study the effects of aspirin.</AbstractText>Limitations: <AbstractText Label="Limitations" NlmCategory="UNASSIGNED">This is not a randomized controlled trial, and therefore, causality cannot be determined.</AbstractText>Conclusions: <AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Aspirin use in chronic kidney disease patients was not associated with reduction in primary or secondary CVD events, progression to kidney failure, or major bleeding.</AbstractText>